Valuation: The Medicines Company

Market Cap 6.79B 6.19B 5.7B 5.18B 9.73B 629B 10.22B 69.36B 27.57B 343B 25.48B 24.94B 1,078B P/E 2017
-2.79x
P/E 2018 -11.4x
Enterprise Value 7.34B 6.69B 6.16B 5.61B 10.52B 680B 11.05B 75B 29.81B 371B 27.55B 26.97B 1,166B EV / Sales 2017
55.1x
EV / Sales 2018 319x
Free-Float
92.97%
Yield 2017 *
-
Yield 2018 -
Date Insider Type Main position Quantity % Market Cap. Importance
1/6/20 Issuer sale

Director

52,223 0.0653%
1/6/20
Sarissa Capital Management LP
Issuer saleCompany 4,202,000 5.2569%
1/6/20 Issuer sale

Chief Development Officer

309,362 0.3870%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.14% - - 6.79B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.30%-4.27%+25.01%+75.64% 407B
Weighted average by Cap. +0.30%-5.18%+26.02%+87.88%

Financials

2017 2018
Net sales 44.79M 40.79M 37.59M 34.19M 64.15M 4.15B 67.42M 457M 182M 2.27B 168M 165M 7.11B 6.14M 5.59M 5.15M 4.69M 8.79M 568M 9.24M 62.7M 24.92M 310M 23.03M 22.54M 974M
Net income -708M -645M -595M -541M -1.01B -65.6B -1.07B -7.24B -2.88B -35.83B -2.66B -2.6B -112B -123M -112M -103M -94.02M -176M -11.4B -185M -1.26B -500M -6.23B -462M -452M -19.55B
Net Debt 498M 453M 418M 380M 713M 46.1B 749M 5.09B 2.02B 25.18B 1.87B 1.83B 79.02B 552M 503M 463M 421M 790M 51.1B 831M 5.64B 2.24B 27.91B 2.07B 2.03B 87.59B
Logo The Medicines Company
The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a twice-yearly therapy that allows administration during patients routine visits to their healthcare professionals and potentially contributes to improved patient adherence and sustained lower LDL-C levels. The Company is a subsidiary of Novartis AG.
Employees
-
  1. Stock Market
  2. Stocks
  3. MDCO Stock